Deep Fundamental Analysis: Sumitomo Chemical India Limited
Current Data Date: 27 January 2026 (Today)
Current Market Price (CMP): ₹405 – ₹410 (Live Update: Stock fell ~3-4% today post-results)
⚠️ CRITICAL UPDATE: Q3 FY26 RESULTS (ANNOUNCED TODAY)
Special Note: Sumitomo Chemical India ne aaj hi (27 January 2026) apne Q3 FY26 ke natije ghoshit kiye hain. Ye numbers market hours me aaye aur market ne iska Negative Reaction diya hai. Q3 performance weak rahi hai, lekin 9-month (pure saal) ka trend abhi bhi stable hai.
1️⃣ Business Model & Work
- Core Business: Ye Japan ki chemical giant Sumitomo Chemical Company (SCC) ki Indian subsidiary hai. Ye Agrochemicals (kheti ki dawaiyan), Animal Nutrition, aur Environmental Health products banati hai.
- Unique Advantage (The MOAT):
- Parent Support: Inhe Japan se proprietary (patented) molecules milte hain jo India me koi aur nahi bana sakta.
- Mix: Inka business Technicals (Raw material) aur Formulations (Final product) dono me hai.
- Revenue Mix:
- Agro Solutions: ~80-85% (Insecticides, Herbicides, Fungicides, Plant Growth Regulators).
- Exports: ~20-22% (Increasing focus). Japan aur Africa markets me strong supply chain hai.
2️⃣ Industry & Sector Analysis
- Sector Status: Agrochemicals (Challenging Phase). Pura sector inventory glut (zyada stock) aur China ki dumping se pareshan hai.
- Current Headwind: Is saal Q3 me “Inventory Destocking” aur “Erratic Monsoon” (Rabi season delay) ne demand par asar dala hai.
- Positive Tailwinds: “China Plus One” strategy ke tehat global companies India se sourcing badha rahi hain, jisme Sumitomo (Japanese parent) ka India unit sabse bada beneficiary hai.
3️⃣ Latest Financial Performance (STRICT DATA RULE)
Data Source: Q3 FY26 Results (Announced 27 Jan 2026) / Exchange Filings
| Metric (Consolidated) | Q3 FY26 (Dec ’25) | Q3 FY25 (Dec ’24) | Trend |
| Revenue | ₹568 Cr | ₹642 Cr | ↘️ -11.5% (Weak) |
| Net Profit (PAT) | ₹76 Cr | ₹87 Cr | ↘️ -13% (Decline) |
| EBITDA | ₹99.5 Cr | ₹106 Cr | ↘️ -6.2% |
| EBITDA Margin | 17.8% | 16.6% | 🟢 Improved (+120 bps) |
| 9-Month Profit | ₹432 Cr | ₹403 Cr | 🟢 +7.2% (YTD Growth) |
- CRITICAL ANALYSIS OF Q3:
- Topline Pressure: Revenue 11.5% girna dikhata hai ki domestic market me demand abhi bhi weak hai. Pricing pressure high hai.
- Efficiency Save: Revenue girne ke bawajood company ne EBITDA Margin improve kiya (17.8%). Ye dikhata hai ki company ne high-margin specialty products beche hain aur cost control kiya hai.
- Exceptional Item: Company ne ~₹15 Cr ka provision kiya hai naye Labor Codes ke liye, jisne reported profit ko thoda aur daba diya.
4️⃣ Management & Shareholding (Latest Pattern – Dec 2025)
- Promoters (Sumitomo Japan):75.00% (Max Allowed).
- Trust Factor: Japanese parent ka 75% stake hold karna sabse bada comfort hai. Unka long-term vision India ko “Global Manufacturing Hub” banane ka hai.
- FIIs (Foreign Investors): 3.37% (↘️ Thoda ghataya hai from 3.65%).
- DIIs (Mutual Funds): ~8.6% (Stable). Domestic institutions (jaise LIC/Mutual Funds) ne holding banaye rakhi hai.
- Governance: Governance gold standard hai. Related party transactions (Parent ke saath len-den) transparent hote hain.
5️⃣ Valuation (Latest Market Data)
- Current Market Price (CMP): ~₹406
- Market Cap: ~₹20,300 Cr.
- P/E Ratio:~38x – 40x (Trailing).
- Comparison: PI Industries (~35x), UPL (~25x but debt heavy), Bayer CropScience (~32x).
- View: Sumitomo hamesha premium valuation par trade karta hai kyunki iski balance sheet clean hai aur parent strong hai. 40x PE sasta nahi hai, lekin quality ke liye market ye premium deta hai.
- Price to Book (P/B): ~6.5x.
6️⃣ Future Growth Triggers (3–5 Years)
- New Molecules (Parent Pipeline): Parent company (SCC Japan) agle 2-3 saalon me 5 naye proprietary products India me launch karne wali hai. Ye high-margin products honge.
- Capex Plan: Company ne ~₹300-400 Cr ka capex plan kiya hai capacity expansion ke liye. Ye naya production parent ko export karne ke liye use hoga.
- Glyphosate Ban Impact: Halanki Glyphosate par restrictions hain, lekin company ke paas diversified portfolio hai jo risk ko dilute karta hai.
7️⃣ Present Situation (Current Outlook)
- Stock Phase: Correction / Support Testing. Q3 results ke baad stock apne 52-week low (~₹396) ke paas aa gaya hai.
- Sentiment: Negative due to weak Q3. Market “Recovery” ka wait kar raha tha, jo delay ho gayi hai.
- Silver Lining: 9-Month (Apr-Dec) ka performance abhi bhi positive (+7% Profit Growth) hai, jo dikhata hai ki saal ka overall result kharab nahi hoga.
8️⃣ Risk & Red Flags
- Seasonal Volatility: Agrochemical business monsoon par nirbhar hai. Q3 me dikha ki kharab mausam sales gira sakta hai.
- Inventory Glut: Global market me generic chemicals ki supply zyada hai, jisse prices dabav me hain.
- Valuation vs Growth: 40x PE par agar growth negative aati hai (jaise aaj Q3 me aayi), to stock me time correction lamba chal sakta hai.
9️⃣ Final Verdict
- View: ACCUMULATE ON DIPS (Long Term Portfolio Stock)
- Risk Profile: Low to Moderate (Debt-free, MNC Parent).
- Target Expectation: 15% CAGR over 3-5 Years.
Summary Points:
- ❌ Weak Q3: Revenue aur Profit dono gire hain (-11% & -13%). Short term pain visible hai.
- ✅ Margin Resilience: Sales girne ke baad bhi margins badhana (17.8%) management ki quality dikhata hai.
- ✅ Strong Parent: Sumitomo Japan ka India focus (China se shift hokar) sabse bada long-term trigger hai.
- ✅ Clean Balance Sheet: Zero Debt aur high cash reserves (~₹2,500 Cr+) company ko mushkil waqt me strong rakhte hain.
- Strategy: Current price (₹406) par stock 52-week low ke paas hai. Ye long-term investors ke liye ek accha entry point ho sakta hai. Aggressive buying na karein, dheere-dheere add karein.